Posts by:
HITLAB, the health innovation and technology organization, today announced the launch of HealthTech Launchpad USA, a new commercialization program designed to help healthcare and life sciences innovators — particularly those outside the U.S. — translate strong technology into real traction in the American market.
HITLAB, the health innovation and technology organization, launched Breakthrough Alliance Asia at a kickoff event in Seoul, extending its flagship startup-corporate partnership program into the Asia-Pacific region for the first time.
This report presents HITLAB’s independent evaluation of Inmedix CloudHRV®, an FDA-cleared autonomic diagnostic platform designed to support precision inflammatory disease management through medical-grade heart rate variability analytics. Built on the framework of immuno-autonomics, the platform enables physiologic assessment of autonomic dysfunction and supports scalable, data-driven approaches to chronic disease care.
The strategic collaboration connects HITLAB’s healthcare investor network and health-system relationships with SpotitEarly as the company prepares for U.S. commercialization of its Bio-AI Hybrid breath test
Predicting an individual’s timing of the menopausal transition remains an unmet clinical need. Conventional biomarkers (AMH, FSH) cannot provide long-range forecasting. LifeAhead applies a validated stochastic follicle-depletion model (Lawley et al., Science Advances, 2024) to generate individualized menopause forecasts from ovarian reserve markers and patient demographics.
